Navigation Links
Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit
Date:10/8/2008

Arizona Heart Institute Pioneers Research That May Offer New Hope to Heart Failure Patients

PHOENIX, Oct. 8 /PRNewswire/ -- Nationally, over 3,000 people are waiting for a heart transplant - and a new lease on life. Sadly, only half of those will receive a transplant. Now, pioneering research at Arizona Heart Institute (AHI) is paving the way for how to treat congestive heart failure (CHF) patients.

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/ahi/35313/

Called MyoCell(R) Muscle Stem Cell Therapy, the unique transplant procedure actually uses skeletal muscle stem cells (myoblasts) from the patient's own body that are injected into the heart. This may create new functioning heart muscle.

Arizona Heart Institute has extensive knowledge in this area, having already completed two myoblast transplantation research studies in patients suffering from congestive heart failure (CHF), the first in 2002 involving the direct injection of myoblast cells into the heart during open heart surgery, and in 2004, the nation's first delivery of myoblast cells using a minimally invasive, catheter-based approach.

Results of these early-phase studies indicate myoblast therapy may improve contractility of heart muscle. Today, AHI is involved in the next stages of myoblast research with the potential to bring myoblast stem cell therapy for eligible CHF patients one step closer to commercialization.

Arizona Heart Institute is part of the MARVEL (Phase II/III Study to Assess Safety and Efficacy of Myoblast Implementation Into Myocardium Post Myocardial Infarction(s)) multicenter trial sponsored by BioHeart, Inc., to further investigate the stem cell implementation procedure.

"The MARVEL research study may lead to the future of medicine for CHF," said Edward B. Diethrich, the study's principal investigator at AHI, founder and medical director of Arizona Heart Institute and Arizona Heart Hospital. "The myoblast cells are derived from a patient's own skeletal muscle tissue thereby reducing risk of rejection. Further, myoblasts can be delivered to the heart muscle in a minimally invasive fashion via a catheter under local anesthesia. Quite literally, a patient may be able to heal their own heart."

Congestive Heart Failure is a condition in which the heart cannot pump enough oxygen-rich blood to the body's other organs, often as a result of prior heart attack. As blood flow out of the heart slows, blood returning to the heart through the veins backs up, causing congestion in the tissues. Patients with CHF often experience swelling, fatigue and shortness of breath. It affects over five million Americans today.

Patients with CHF have portions of the heart muscle that are severely damaged, usually due to a heart attack. Unlike other tissues in the body, the human heart does not have the ability to repair itself, weakening the heart muscle's ability to function as it did before the heart attack. Without treatment, the heart may grow weaker, eventually resulting in an irreversible situation. Patients with advanced, severe heart failure that do not respond to any treatment method may be considered for heart transplantation. The hope is that Myoblast Therapy may someday replace heart transplantation as the primary option for patients with severe CHF, giving them a new lease on life.

To date, upwards of 235 CHF patients have been treated worldwide using myoblasts. Myoblast transplantation for congestive heart failure is investigational and not approved commercially in the U.S. To be eligible for the MARVEL research study, a patient must be diagnosed with chronic Class II - IV CHF, stable and on optimal medical therapy for at least 60 days, and between the ages of 18-80. To make an appointment at Arizona Heart Institute, or for more information about the MARVEL research study, please call (602) 707-4000, or visit http://www.azheart.com


'/>"/>
SOURCE Arizona Heart Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
3. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
4. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
5. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
6. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
7. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
8. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
9. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
10. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
11. Video: Sanford Healths Journey to Cure Type 1 Diabetes Receives Major Boost
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... The report " Automated Breast Ultrasound System (ABUS) Market ... End User (Hospitals, Diagnostic Imaging Centers), Industry Analysis Report, Regional Outlook (U.S., ... , Germany , UK, France , ... , China , Japan , ... Saudi Arabia , UAE, South Africa ), ...
(Date:1/18/2017)... , Jan. 18, 2017  Tarix Orphan LLC today ... granted a Rare Pediatric Disease (RPD) designation for the ... Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. ... treatment is limited to supportive care. "The ... Drug Designation previously granted by the FDA in this ...
(Date:1/18/2017)... 2017  Astellas Pharma Inc. (President and CEO: ... its participation in Access Accelerated, a global, multi-stakeholder ... prevention, diagnostics and treatment in low-income and lower-middle ... companies and in collaboration with the World Bank ... (UICC), Astellas will work towards the United Nations ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... Metro ... approach to infusing high speed technology into the fabric of an entire community. ... advancement of healthcare and wellness in a yet-to-be-named, health focused campus. Leading this ...
(Date:1/17/2017)... ... ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting provider , is proud ... Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted that Mirror Mirror Beauty ... by Zeltiq, CoolSculpting is approved by the Food and Drug Administration as a safe ...
(Date:1/17/2017)... ... January 17, 2017 , ... Peoples Health ... Peoples Health network on Dec. 1, 2016. Peoples Health, a Metairie-based Medicare Advantage ... is an exciting addition to our provider network, and the addition will benefit ...
(Date:1/17/2017)... , ... January 17, 2017 , ... A prescription medication ... of the fourth Cradle to Cradle Product Design Challenge , the Cradle ... a series of six circular design challenges scheduled to run through early 2018. The ...
(Date:1/17/2017)... ... 2017 , ... Neil H. Greco Insurance Agency, a northern New Jersey firm ... is launching a charity drive to raise awareness of heart disease and promote habits ... America, and is responsible for 1 in every 4 deaths at the national level ...
Breaking Medicine News(10 mins):